Alimera Sciences Added to NASDAQ Biotechnology Index
PR Newswire - Tue Dec 16, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ALIM: 5.43 (-0.06)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management
PR Newswire - Mon Dec 15, 7:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the holder is prohibited from converting Series B Preferred Stock into shares of Alimera's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of Alimera's common stock then issued and outstanding. Alimera also issued an additional 124.378 shares of Series B Preferred Stock to Deerfield as a subscription premium. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Preferred Stock does not have voting rights. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.43 (-0.06)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Insider Trading Alert - OUTR, ALIM And CINF Traded By Insiders
at The Street - Wed Dec 03, 12:00PM CST
Stocks with insider trader activity include OUTR, ALIM and CINF
CINF: 52.18 (-0.19), ALIM: 5.43 (-0.06), OUTR: 72.88 (-2.00)
Iluvien cleared in the Netherlands
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:28PM CST
ALIM: 5.43 (-0.06), PSDV: 4.00 (-0.03)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Dec 01, 2:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization in the Netherlands to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)
Alimera secures new financing
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:57AM CST
ALIM: 5.43 (-0.06)
Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
PR Newswire - Fri Nov 28, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates ("Deerfield"
ALIM: 5.43 (-0.06)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)
Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)
Alimera Sciences' (ALIM) CEO Daniel Myers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:46PM CST
ALIM: 5.43 (-0.06)
Alimera Sciences beats by $0.48, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST
ALIM: 5.43 (-0.06)
Alimera Sciences (ALIM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
ALIM: 5.43 (-0.06)
Alimera Sciences Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:13PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the third quarter ended September 30, 2014.
ALIM: 5.43 (-0.06)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.48 (-0.15), ACET: 21.85 (-0.07), ANET: 65.00 (+0.30), FNGN: 37.85 (+0.79), CPST: 0.74 (+0.01), AUQ: 3.08 (+0.10), AMRN: 0.99 (unch), ED: 66.91 (+0.90), ENV: 51.94 (+1.62), FXCM: 16.88 (-0.12), BCEI: 23.25 (-0.62), GXP: 28.09 (+0.35), EAC: 8.13 (+0.02), DXCM: 54.94 (+0.99), CSC: 64.36 (+0.24), AEL: 28.73 (+0.12), HNSN: 0.55 (-0.02), CFN: 59.18 (+0.04), ANAC: 30.58 (+0.16), DAR: 18.35 (-0.06), GST: 2.47 (-0.03), ARC: 9.80 (+0.12), FIVN: 4.56 (+0.11), ELON: 1.72 (+0.03), FSLR: 43.67 (-0.39), EZPW: 11.48 (-0.20), ALIM: 5.43 (-0.06), FWM: 2.80 (-0.03), BRS: 64.93 (+0.02), ECOM: 21.95 (+0.19), FTEK: 3.73 (+0.03), CVT: 27.66 (+0.26), AL: 34.20 (+0.12), BBRG: 12.66 (-0.18), BPZ: 0.25 (+0.03), ECPG: 43.81 (-0.11), HTGC: 15.13 (+0.39), AIRM: 43.03 (-0.10), BNFT: 32.78 (+0.75), ENOC: 15.37 (+0.03), HPTX: 21.91 (-0.08), AGO: 26.28 (+0.23), FICO: 72.85 (+0.40), FF: 13.09 (+0.23), FI: 16.80 (-0.22), EVC: 6.59 (+0.09), EBS: 27.64 (+1.28), ABCO: 49.30 (-0.58), DIOD: 27.55 (+0.29), DIS: 94.42 (-0.27), EGOV: 18.66 (+0.19), APEI: 36.33 (+0.24), DVA: 76.06 (+0.07), CLVS: 54.58 (+0.43), HCI: 45.48 (-0.09), BRKR: 19.50 (+0.09), HGR: 23.20 (+0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 8.52 (+0.05), ALIM: 5.43 (-0.06), ACHN: 13.06 (+1.22), FNHC: 25.30 (+0.45), ARCP: 8.33 (unch), CKEC: 26.09 (+0.10), JAXB: 12.26 (+0.96), PCLN: 1,149.78 (+2.17), TESO: 12.71 (-0.42)